Kratom is the leaf of Mitragyna speciosa, a Southeast Asian tree. 7-hydroxymitragynine (7-OH) is one of its alkaloids — present naturally in very small amounts but now sold in concentrated synthesized forms that act much more opioid-like. This guide covers dependence, withdrawal, safety risks, and when buprenorphine may be considered.
This guide is educational. It is not a self-start medication guide. Your exact medication plan, start timing, dose changes, rescue plan, and follow-up should come from your MyStreetHealth provider.
Do not start, stop, split, skip, add, or change medications unless your provider tells you to. For medical emergencies, call 911 or go to the emergency room.
What is the difference between kratom and 7-OH?
Kratom is a plant. 7-OH (7-hydroxymitragynine) is one of the alkaloids found in that plant — present naturally in very small amounts (often less than 0.05% of leaf dry weight, per FDA's 7-OH scientific assessment). When you consume kratom, your body also produces a small amount of 7-OH endogenously as a metabolite of mitragynine. Manufacturers have begun isolating or synthesizing pure 7-OH and selling it in concentrated products, which contain 7-OH in amounts far beyond what occurs naturally.
How does kratom or 7-OH dependence develop?
Repeated use of kratom or concentrated 7-OH can produce tolerance, physical dependence, withdrawal, cravings, and loss of control — the same opioid-like adaptation pattern seen with traditional opioids. The WHO 44th ECDD pre-review describes both mitragynine and 7-OH as partial mu-opioid receptor agonists. Because 7-OH is more potent at the mu-receptor than mitragynine, dependence may develop faster and feel more intense with concentrated 7-OH products than with plain kratom leaf.
When may buprenorphine be considered for kratom or 7-OH dependence?
Because kratom and 7-OH act on the mu-opioid receptor system, buprenorphine — a partial mu-opioid receptor agonist used to treat opioid use disorder (SAMHSA) — may be considered when the pattern looks opioid-like: withdrawal, cravings, tolerance, escalation, and loss of control. Treatment is individualized; the start plan depends on the product type, the last use, withdrawal severity, and other medications. Care begins with a clinical visit, not with a self-start medication.
Care
Trying to stop kratom or 7-OH — and can't?
Treatment overview. What care looks like at MyStreetHealth.
Care
Can Suboxone help kratom withdrawal?
How buprenorphine may help kratom and concentrated 7-OH withdrawal.
Care
How to switch from kratom to Suboxone
What physician-guided transition means, why timing matters, and what to expect.
How do kratom, 7-OH, and buprenorphine actually work?
A focused science page on receptors, potency, partial agonists, biased agonism, and why concentrated 7-OH products are clinically different from plain kratom leaf. Optional reading for patients who want the deeper pharmacology — grounded in FDA and WHO sources, with caveats where the science is still evolving.
- U.S. Food and Drug Administration — FDA and Kratom.
- U.S. Food and Drug Administration — Products Containing 7-OH Can Cause Serious Harm.
- World Health Organization — 44th ECDD Pre-Review of Kratom (Mitragyna speciosa) and Its Alkaloids.
- SAMHSA — What is Buprenorphine?
- American Society of Addiction Medicine — National Practice Guideline.
Last reviewed: May 2026 · Reviewed by: MyStreetHealth Medical Team
